非小細(xì)胞肺癌中EGFR表達(dá)及其啟動(dòng)子甲基化的臨床意義研究
發(fā)布時(shí)間：2019-06-21 05:30
【摘要】：EGFR基因位于第7號(hào)染色體的p1 1.2,編碼橫跨細(xì)胞膜表面的糖蛋白受體。EGFR為酪氨酸激酶受體,是蛋白激酶家族重要一員。EGFR與其配體結(jié)合成二聚體,隨后酪氨酸自身磷酸化啟動(dòng)下游各通路,從而調(diào)節(jié)細(xì)胞的增殖,分化,凋亡等。在多種癌癥中EGFR信號(hào)通路的改變導(dǎo)致了癌細(xì)胞更難以被清除。大量文獻(xiàn)報(bào)道EGFR蛋白的高表達(dá)與多種腫瘤的分期和預(yù)后相關(guān)。近年來(lái)表觀遺傳學(xué)的調(diào)控機(jī)制已經(jīng)成為研究的熱點(diǎn),表觀遺傳學(xué)信息是指基因的DNA序列未發(fā)生變化而表型發(fā)生了改變,并且這種改變?cè)诎l(fā)育和細(xì)胞增殖過(guò)程中能穩(wěn)定遺傳。DNA甲基化是表觀遺傳學(xué)調(diào)控機(jī)制之一。本研究旨在研究非小細(xì)胞肺癌中EGFR表達(dá)與臨床各指標(biāo)間的聯(lián)系,并探討EGFR啟動(dòng)子甲基化調(diào)控的改變與EGFR表達(dá)間的相關(guān)性。[目的]1.應(yīng)用免疫印跡法檢測(cè)肺癌組織和正常組織樣本中EGFR蛋白表達(dá),并研究樣本中EGFR表達(dá)水平與組織分類(lèi),臨床分期,樣本病理等臨床資料的相關(guān)性。2.應(yīng)用甲基化特異性PCR檢測(cè)肺癌組織和正常組織樣本中EGFR基因啟動(dòng)子區(qū)CpG島甲基化情況,并研究樣品中EGFR啟動(dòng)子甲基化水平與EGFR的表達(dá)差異間的相關(guān)性。[方法]1.收集2015年12月至2016年5月間云南省腫瘤醫(yī)院收治的手術(shù)切除的50例非小細(xì)胞肺癌患者的癌組織與正常組織樣本。入選標(biāo)準(zhǔn)為:①手術(shù)切除標(biāo)本經(jīng)病理診斷為非小細(xì)胞肺癌②術(shù)前未經(jīng)過(guò)任何抗腫瘤治療③腫瘤經(jīng)手術(shù)切除,切緣為陰性。④年齡≥30歲,≤75歲。2.將病人標(biāo)本收回后,用液氮冰凍后至-80℃冰箱中保存。組織研磨后用試劑盒提取DNA,用Ripa提取蛋白,并測(cè)定其吸光度和濃度。提取后放回-80℃冰箱中保存待后續(xù)處理。3.BCA測(cè)定蛋白濃度,并使用Western-blot測(cè)定EGFR的蛋白表達(dá)。4.提取的DNA進(jìn)行急速重亞硫酸鹽處理,并用甲基化引物進(jìn)行擴(kuò)增,運(yùn)用瓊脂糖凝膠電泳,觀測(cè)其表達(dá)差異。5.Western-blot 結(jié)果采用圖像分析處理軟件(ImageJ,National Institutes of Health)進(jìn)行半定量分析。6.應(yīng)用SPSS20.0軟件包的分析和統(tǒng)計(jì),各組間實(shí)驗(yàn)數(shù)據(jù)進(jìn)行正態(tài)分布,方差齊性檢驗(yàn),非正態(tài)分布數(shù)據(jù)之間的差異用卡方(chi-square test)和秩和(Wilcoxon signed ranks test)檢驗(yàn)法,應(yīng)用非線(xiàn)性相關(guān)分析進(jìn)行相關(guān)性分析。[結(jié)果]1.在非小細(xì)胞肺癌中癌和正常組織中EGFR的表達(dá)有統(tǒng)計(jì)學(xué)差異(p=0.009),EGFR在癌中高表達(dá)。2.EGFR的表達(dá)與淋巴結(jié)轉(zhuǎn)移有統(tǒng)計(jì)學(xué)意義(p=0.008) , EGFR表達(dá)越高,淋巴結(jié)轉(zhuǎn)移的可能性增加,兩者呈正相關(guān)。3.EGFR的表達(dá)與EGFR啟動(dòng)子區(qū)甲基化具有統(tǒng)計(jì)學(xué)意義(p=0.025),甲基化程度降低時(shí)EGFR的表達(dá)上調(diào),兩者呈負(fù)相關(guān)。[結(jié)論]1.EGFR在肺癌組織中相對(duì)高表達(dá),且EGFR在肺癌的癌組織中相對(duì)表達(dá)與淋巴結(jié)轉(zhuǎn)移相關(guān),說(shuō)明EGFR的表達(dá)可能成為臨床上判斷疾病進(jìn)展的指標(biāo)和治療的靶點(diǎn)。2.EGFR的表達(dá)與甲基化的改變具有相關(guān)性,肺癌的癌組織中EGFR啟動(dòng)子相對(duì)低甲基化時(shí)EGFR表達(dá)有增高趨勢(shì),EGFR啟動(dòng)子相對(duì)高甲基化時(shí)EGFR表達(dá)有降低趨勢(shì),所以EGFR的表達(dá)可能與啟動(dòng)子甲基化狀態(tài)相關(guān),為以EGFR為靶點(diǎn)的腫瘤靶向治療提供了新的思路。
[Abstract]:The EGFR gene is located at p1 1.2 of chromosome 7 and encodes a glycoprotein receptor across the surface of the cell membrane. EGFR is a tyrosine kinase receptor and is an important member of the protein kinase family. EGFR binds to its ligand to form a dimer, followed by tyrosine autophosphorylation to initiate downstream pathways, thereby modulating cell proliferation, differentiation, apoptosis, and the like. The change in the EGFR signaling pathway in a variety of cancers leads to a more difficult removal of cancer cells. A large number of literature reports that the high expression of the EGFR protein is associated with the staging and prognosis of a variety of tumors. In recent years, the control mechanism of epigenetics has become the hot spot of the research, and the epigenetic information is that the DNA sequence of the gene has not changed and the phenotype has changed, and the change can be stably inherited in the course of development and cell proliferation. DNA methylation is one of the mechanisms of epigenetic control. The purpose of this study was to study the relationship between EGFR expression in non-small cell lung cancer and the clinical indicators, and to explore the relationship between the change of EGFR promoter methylation and the expression of EGFR. [Objective] 1. The expression of EGFR in lung cancer tissues and normal tissue samples was detected by immunoblotting method, and the correlation of the expression level of EGFR in the samples with the clinical data such as tissue classification, clinical stage and sample pathology was studied. Methylation-specific PCR was used to detect the methylation of the CpG island in the promoter region of the EGFR gene in the lung cancer tissue and the normal tissue sample, and the relationship between the methylation level of the EGFR promoter and the expression of EGFR in the sample was studied. [Method] 1. To collect 50 non-small cell lung cancer patients with non-small cell lung cancer and normal tissue samples from December 2015 to May 2016. The inclusion criteria were as follows: the surgical resection of the specimens was performed by the pathologic diagnosis of non-small cell lung cancer without any anti-tumor treatment, and the tumor was removed by operation and the cut edge was negative. She is 30 years old and 75 years of age. After the patient's specimen was recovered, the patient was frozen with liquid nitrogen and stored in a-80.degree. C. refrigerator. After the tissue was ground, the DNA was extracted with the kit, and the protein was extracted with the Ripa and its absorbance and concentration were determined. And the protein concentration of the EGFR was measured by Western-blot, and the protein expression of the EGFR was determined by Western-blot. The extracted DNA was subjected to rapid bisulfite treatment and amplified by a methylation primer, and the expression difference was observed by agarose gel electrophoresis. Based on the analysis and statistics of the SPSS10.0 software package, the normal distribution, the homogeneity test and the non-normal distribution data between the groups were analyzed by the chi-square test and the Wilcoxon signed test, and the correlation analysis was carried out with the non-linear correlation analysis. [Results] 1. The expression of EGFR in non-small cell lung cancer and normal tissue was statistically different (p = 0.009), and EGFR was highly expressed in cancer.2. The expression of EGFR and lymph node metastasis were of statistical significance (p = 0.008), and the higher the expression of EGFR, the possibility of lymph node metastasis was increased. There was a positive correlation between the expression of EGFR and the methylation of EGFR promoter region (p = 0.025). [Conclusion] 1. EGFR is relatively highly expressed in lung cancer tissues, and the relative expression of EGFR in the cancer tissues of lung cancer is related to lymph node metastasis, and it is indicated that the expression of EGFR may be a target for clinical judgment of disease progression and the target of treatment.2. The expression of EGFR is related to the change of methylation. In the case of lung cancer, the expression of EGFR is increased in the case of relatively low methylation of the EGFR promoter, and the expression of EGFR in the case of relatively high methylation of the EGFR promoter tends to decrease, so the expression of EGFR may be related to the methylation state of the promoter, and a new idea is provided for the target therapy of the tumor targeting EGFR.
【學(xué)位授予單位】：昆明醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類(lèi)號(hào)】：R734.2
本文編號(hào)：2503826
[Abstract]:The EGFR gene is located at p1 1.2 of chromosome 7 and encodes a glycoprotein receptor across the surface of the cell membrane. EGFR is a tyrosine kinase receptor and is an important member of the protein kinase family. EGFR binds to its ligand to form a dimer, followed by tyrosine autophosphorylation to initiate downstream pathways, thereby modulating cell proliferation, differentiation, apoptosis, and the like. The change in the EGFR signaling pathway in a variety of cancers leads to a more difficult removal of cancer cells. A large number of literature reports that the high expression of the EGFR protein is associated with the staging and prognosis of a variety of tumors. In recent years, the control mechanism of epigenetics has become the hot spot of the research, and the epigenetic information is that the DNA sequence of the gene has not changed and the phenotype has changed, and the change can be stably inherited in the course of development and cell proliferation. DNA methylation is one of the mechanisms of epigenetic control. The purpose of this study was to study the relationship between EGFR expression in non-small cell lung cancer and the clinical indicators, and to explore the relationship between the change of EGFR promoter methylation and the expression of EGFR. [Objective] 1. The expression of EGFR in lung cancer tissues and normal tissue samples was detected by immunoblotting method, and the correlation of the expression level of EGFR in the samples with the clinical data such as tissue classification, clinical stage and sample pathology was studied. Methylation-specific PCR was used to detect the methylation of the CpG island in the promoter region of the EGFR gene in the lung cancer tissue and the normal tissue sample, and the relationship between the methylation level of the EGFR promoter and the expression of EGFR in the sample was studied. [Method] 1. To collect 50 non-small cell lung cancer patients with non-small cell lung cancer and normal tissue samples from December 2015 to May 2016. The inclusion criteria were as follows: the surgical resection of the specimens was performed by the pathologic diagnosis of non-small cell lung cancer without any anti-tumor treatment, and the tumor was removed by operation and the cut edge was negative. She is 30 years old and 75 years of age. After the patient's specimen was recovered, the patient was frozen with liquid nitrogen and stored in a-80.degree. C. refrigerator. After the tissue was ground, the DNA was extracted with the kit, and the protein was extracted with the Ripa and its absorbance and concentration were determined. And the protein concentration of the EGFR was measured by Western-blot, and the protein expression of the EGFR was determined by Western-blot. The extracted DNA was subjected to rapid bisulfite treatment and amplified by a methylation primer, and the expression difference was observed by agarose gel electrophoresis. Based on the analysis and statistics of the SPSS10.0 software package, the normal distribution, the homogeneity test and the non-normal distribution data between the groups were analyzed by the chi-square test and the Wilcoxon signed test, and the correlation analysis was carried out with the non-linear correlation analysis. [Results] 1. The expression of EGFR in non-small cell lung cancer and normal tissue was statistically different (p = 0.009), and EGFR was highly expressed in cancer.2. The expression of EGFR and lymph node metastasis were of statistical significance (p = 0.008), and the higher the expression of EGFR, the possibility of lymph node metastasis was increased. There was a positive correlation between the expression of EGFR and the methylation of EGFR promoter region (p = 0.025). [Conclusion] 1. EGFR is relatively highly expressed in lung cancer tissues, and the relative expression of EGFR in the cancer tissues of lung cancer is related to lymph node metastasis, and it is indicated that the expression of EGFR may be a target for clinical judgment of disease progression and the target of treatment.2. The expression of EGFR is related to the change of methylation. In the case of lung cancer, the expression of EGFR is increased in the case of relatively low methylation of the EGFR promoter, and the expression of EGFR in the case of relatively high methylation of the EGFR promoter tends to decrease, so the expression of EGFR may be related to the methylation state of the promoter, and a new idea is provided for the target therapy of the tumor targeting EGFR.
【學(xué)位授予單位】：昆明醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類(lèi)號(hào)】：R734.2
【參考文獻(xiàn)】
相關(guān)期刊論文 前6條
1 王起龍;李敏;胡成平;;吉非替尼可能通過(guò)EGFR啟動(dòng)子甲基化誘導(dǎo)肺腺癌細(xì)胞繼發(fā)性耐藥[J];中國(guó)肺癌雜志;2015年04期
2 滿(mǎn)朝來(lái);唐高霞;趙麗;李鳳;甄鑫;;DNA甲基化與microRNA[J];中國(guó)生物工程雜志;2014年08期
3 饒麗華;黃孝文;許勝;;Lin28/Let-7調(diào)節(jié)環(huán)分子機(jī)制及相關(guān)因子研究進(jìn)展[J];臨床耳鼻咽喉頭頸外科雜志;2014年09期
4 孫俊杰;吳建中;陸建偉;曹海霞;馬蓉;馮繼鋒;;人非小細(xì)胞肺癌細(xì)胞EGFR基因啟動(dòng)子甲基化與吉非替尼敏感性之間的相關(guān)性研究[J];臨床腫瘤學(xué)雜志;2012年09期
5 郭琛;郭其森;曾洪生;禚銀玲;管燕;劉秀菊;;非小細(xì)胞肺癌患者腫瘤組織與外周血中EGFR表達(dá)相關(guān)性研究[J];中國(guó)肺癌雜志;2010年12期
6 陳壽松;肖同浩;陳昕薇;彭正銀;梁勵(lì)瑋;;EGFR、COX-2及P63蛋白在非小細(xì)胞肺癌中的表達(dá)及其意義[J];第三軍醫(yī)大學(xué)學(xué)報(bào);2008年07期
，本文編號(hào)：2503826
本文鏈接：http://www.sikaile.net/yixuelunwen/zlx/2503826.html
最近更新
教材專(zhuān)著
